Omics testing of blood and spinal fluid to find Alzheimer’s biomarkers in diverse communities

HABS-HD - Core D - Omics Core

NIH-funded research University of North Texas Hlth Sci Ctr · NIH-11173824

This project uses blood and spinal fluid from African American, Mexican American, and non‑Hispanic White people to find biological signs that could help detect and track Alzheimer’s disease.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionUniversity of North Texas Hlth Sci Ctr NIH-funded
Lab location1 site (Fort Worth, United States)
Project IDNIH-11173824 on NIH RePORTER

What this research studies

The Omics Core collects, processes, and stores blood and cerebrospinal fluid samples from participants of different racial and ethnic backgrounds. It applies multi‑level omics methods (for example, proteomics and other large‑scale molecular tests) and compares findings with established amyloid, tau, and neurodegeneration (AT[N]) biomarkers. Samples and data are shared with the study’s projects to identify patterns linked to mild cognitive impairment and dementia. The work focuses on finding population‑specific biomarker signatures that could inform diagnosis and more appropriately tailored clinical trials.

Who could benefit from this research

Good fit: Adults (people with normal cognition, mild cognitive impairment, or Alzheimer’s dementia) who are African American, Mexican American, or non‑Hispanic White and willing to provide blood and possibly spinal fluid samples.

Not a fit: People who cannot or do not want to give blood or spinal fluid samples, or who are not in the included racial/ethnic groups, are unlikely to participate or directly benefit from this core.

Why it matters

Potential benefit: If successful, this could produce more accurate, population‑specific blood or spinal fluid tests and help design treatments and trials that better fit different groups.

How similar studies have performed: Prior biomarker studies, including proteomic and plasma AT(N) markers, have shown promise for detecting MCI and neurodegeneration, but a large multi‑omics comparison across these diverse groups is novel.

Where this research is happening

Fort Worth, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer disease dementia
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.